DZD8586 Clinical Trials

4 actively recruiting trials across 1 location

Also known as: Birelentinib

Pipeline

Phase 1: 1Phase 2: 2Phase 3: 1

Top Sponsors

Dizal Pharmaceuticals2
Dizal (Jiangsu) Pharmaceutical Co., Ltd.2

Indications

Cancer4
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma3
Lymphoma, Non-Hodgkin1

Other3 trials

A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)

Phase 2

A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)

Phase 3

DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)

Phase 2

New York, New York1 trial

DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Research site

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.